Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05TWD
|
|||
| Former ID |
DIB006575
|
|||
| Drug Name |
Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy
|
|||
| Synonyms |
MultiGeneAngio; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease); VEGF-114 based therapy (cardiovascular disease), Compugen/MGVS; VEGF-114 based therapy (cardiovascular disease), Compugen/MultiGene Vascular Systems; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease), Compugen/MGVS; Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy (cardiovascular disease), Compugen/MultiGene Vascular Systems
Click to Show/Hide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 1/2 | [1] | |
| Peripheral arterial disease [ICD-11: BD4Z; ICD-10: I73, I73.9; ICD-9: 443] | Phase 1/2 | [2] | ||
| Company |
Compugen Ltd
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00390767) Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.